Methods using phenethanolamine derivatives for treatment of respiratory diseases
AssigneeGlaxo Group Limited
InventorsKeith Biggadike, Diane Mary Coe, Dean David Edney, Stephen Barry Guntrip, Abigail Halton, Brian Edgar Looker, Michael John Monteith, Rebecca Jane Moore, Rajnikant Patel, Panayiotis Alexandrou Procopiou
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.
Claims29
A method for the treatment of a disease associated with reversible airways obstruction selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection and upper respiratory tract disease, which comprises administrating a therapeutically effective amount of a compound of formula (I):
- wherein:
- m is an integer of from 2 to 8;
- n is an integer of from 3 to 11;
- with the proviso that m+n is 5 to 19;
- R1 is —XSO2NR6R7
- wherein X is —(CH2)p— or C2-6 alkenylene;
- R6 and R7 are independently selected from hydrogen, C1-6alkyl,
- C3-7cycloalkyl, C(O)NR8R9, phenyl, and phenyl(C1-4alkyl)-,
- or R6 and R7, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring,
- and R6 and R7 are each optionally substituted by one or two groups selected from halo,
- C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, hydroxy-substituted C1-6alkoxy, —CO2R8, —SO2NR8R9,
- —CONR8R9, —NR8C(O)R9, or a 5-, 6- or 7-membered heterocylic ring;
- R8 and R9 are independently selected from hydrogen, C1-6alkyl,
- C3-6cycloalkyl, phenyl, and phenyl(C1-4alkyl)-;
- and
- p is an integer of from 0 to 6;
- R2 and R3 are independently selected from hydrogen, C1-6alkyl, C1-6alkoxy, halo, phenyl, and
- C1-6haloalkyl;
- and
- R4 and R5 are independently selected from hydrogen and C1-4alkyl with the proviso that the total number of carbon atoms in R4 and R5 is not more than 4, or a pharmaceutically acceptable salt, or solvate thereof, to the mammal.
A method for the treatment of a disease associated with reversible airways obstruction selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection and upper respiratory tract disease, which comprises administrating a therapeutically effective amount of a compound of formula (Ia):
- wherein R1 is —XSO2NR6R7
- wherein X is —(CH2)p— or C2-6 alkenylene;
- R6 and R7 are independently selected from hydrogen, C1-6alkyl,
- C3-7cycloalkyl, C(O)NR8R9, phenyl, and phenyl(C1-4alkyl)-,
- or R6 and R7, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring,
- and R6 and R7 are each optionally substituted by one or two groups selected from halo,
- C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, hydroxy-substituted C1-6alkoxy,
- —CO2R8, —SO2NR8R9,
- —CONR8R9, —NR8C(O)R9, or a 5-, 6- or 7-membered heterocylic ring;
- R8 and R9 are independently selected from hydrogen, C1-6alkyl,
- C3-6cycloalkyl, phenyl, and phenyl(C1-4alkyl)-;
- and
- p is an integer of from 0 to 6;
- or a pharmaceutically acceptable salt, or solvate thereof, to the mammal.
A method for the treatment of a disease associated with reversible airways obstruction selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection and upper respiratory tract disease, which comprises administrating a therapeutically effective amount of a compound of formula (Ib):
- or a salt, solvate, or physiologically functional derivative thereof,
- wherein R1 is —XSO2NR6R7
- wherein X is —(CH2)p— or C2-6 alkenylene;
- R6 and R7 are independently selected from hydrogen, C1-6alkyl,
- C3-7cycloalkyl, C(O)NR8R9, phenyl, and phenyl(C1-4alkyl)-,
- or R6 and R7, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring,
- and R6 and R7 are each optionally substituted by one or two groups selected from halo,
- C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, hydroxy-substituted C1-6alkoxy,
- —CO2R8, —SO2NR8R9,
- —CONR8R9, —NR8C(O)R9, or a 5-, 6- or 7-membered heterocylic ring;
- R8 and R9 are independently selected from hydrogen, C1-6alkyl,
- C3-6cycloalkyl, phenyl, and phenyl(C1-4alkyl)-;
- and
- p is an integer of from 0 to 6;
- or a pharmaceutically acceptable salt, or solvate thereof, to the mammal.
Dependencies are inferred from the claim text.